{"id":"W3049330696","doi":"10.1158/1538-7445.am2020-ct302","title":"Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"TIGIT; Atezolizumab; Medicine; Tolerability; Oncology; Pharmacodynamics; Antibody; Internal medicine; Pharmacokinetics; Pharmacology; Cancer; Immunotherapy; Immunology; Adverse effect; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001350926,0.001941252,0.002009558,0.0006216067,0.0004604002,0.001205126,0.001008705,0.00132302,0.003287598],"category_scores_gemma":[0.0008214042,0.0007099725,0.001365968,0.0005825293,0.000938213,0.000848736,0.000368623,0.004859571,0.0011484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001259403,"about_ca_system_score_gemma":0.002054917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001777724,"about_ca_topic_score_gemma":0.003309425,"domain_scores_codex":[0.999558,0.0001815896,0.00002585632,0.00007865456,0.00005303834,0.0001028753],"domain_scores_gemma":[0.9993923,0.00006825695,0.00009630648,0.00006364286,0.00005378118,0.0003258205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5378749,0.143263,0.007818651,0.0009849832,0.001419817,0.000512567,0.0005288803,0.005236147,0.1879636,0.0004026451,0.006550979,0.1074439],"study_design_scores_gemma":[0.3944311,0.5751411,0.01262202,0.00003517712,0.0004008717,0.0004695096,0.00006009232,0.00160328,0.01218956,0.0001441289,0.002864429,0.00003867911],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919788,0.001255131,0.0006182502,0.0003683829,0.00009149854,0.002319942,0.001405127,0.0001540449,0.001808812],"genre_scores_gemma":[0.9892505,0.0009419924,0.00156144,0.0005220409,0.0001079239,0.002070024,0.002671547,0.0000393153,0.002835273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003287598,"threshold_uncertainty_score":0.01099807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04779853249571873,"score_gpt":0.4007939234105441,"score_spread":0.3529953909148253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}